Related references
Note: Only part of the references are listed.Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update
Arjun Lakshman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma
Reona Sakemura et al.
BLOOD (2022)
Induction of m6A methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance
Zhiming Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
Cesarina Giallongo et al.
ONCOGENESIS (2022)
Bone Marrow Mesenchymal Stromal Cells: Identification, Classification, and Differentiation
Qianmin Gao et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment
Katarina Chroma et al.
CELL DEATH & DISEASE (2022)
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression
Antonio G. Solimando et al.
HAEMATOLOGICA (2021)
Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype
Heather Fairfield et al.
CANCER RESEARCH (2021)
Underweight as a risk factor of mortality in patients with newly diagnosed multiple myeloma
Chun-Kuang Tsai et al.
SUPPORTIVE CARE IN CANCER (2021)
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
Yael C. Cohen et al.
NATURE MEDICINE (2021)
Amino acid deprivation induces AKT activation by inducing GCN2/ATF4/REDD1 axis
Hyeon-Ok Jin et al.
CELL DEATH & DISEASE (2021)
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs
Paula Saavedra-Garcia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
Joseph Mikhael et al.
BLOOD CANCER JOURNAL (2021)
Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression
Andrea Diaz-Tejedor et al.
CANCERS (2021)
Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
Fatih M. Uckun
CANCERS (2021)
Inhibition of the L-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors
Monika K. Prelowska et al.
CANCER LETTERS (2021)
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Lenka Besse et al.
CANCER RESEARCH (2021)
Novel immunotherapies in multiple myeloma - chances and challenges
Leo Rasche et al.
HAEMATOLOGICA (2021)
Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth
Mariachiara Buccarelli et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Cells of the human intestinal tract mapped across space and time
Rasa Elmentaite et al.
NATURE (2021)
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
Madelon M. E. de Jong et al.
NATURE IMMUNOLOGY (2021)
Harnessing the Immune System to Fight Multiple Myeloma
Jakub Krejcik et al.
CANCERS (2021)
Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells
Zsolt Matula et al.
CANCERS (2021)
Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation
Jing Chen et al.
CELLS (2021)
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment
Giada Bianchi et al.
BLOOD CANCER DISCOVERY (2021)
Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model
Alessandro Natoni et al.
HAEMATOLOGICA (2020)
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
Jiro Kikuchi et al.
LEUKEMIA (2020)
Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination
Ilseyar Akhmetzyanova et al.
LEUKEMIA (2020)
IMMUNITY, HYPOXIA, AND METABOLISM-THE MENAGE A TROIS OF CANCER: IMPLICATIONS FOR IMMUNOTHERAPY
Carla Riera-Domingo et al.
PHYSIOLOGICAL REVIEWS (2020)
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Irene M. Ghobrial et al.
CLINICAL CANCER RESEARCH (2020)
Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer
Matthieu Lacroix et al.
MOLECULAR METABOLISM (2020)
Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma
Xuan Wu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow
Anna Petrackova et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response
Shamir Cassim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Myeloma Cells Down-Regulate Adiponectin in Bone Marrow Adipocytes Via TNF-Alpha
Emma Morris et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
Kazutaka Sunami et al.
CANCER SCIENCE (2020)
Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages
Alessio Menga et al.
EMBO MOLECULAR MEDICINE (2020)
SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation
Yu Xiang et al.
LIFE SCIENCES (2020)
Multiple myeloma current treatment algorithms
S. Vincent Rajkumar et al.
BLOOD CANCER JOURNAL (2020)
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis
Chiara Fucci et al.
CELL REPORTS (2020)
Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies
Zhefang Wang et al.
FRONTIERS IN ONCOLOGY (2020)
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
Cinzia Federico et al.
NATURE COMMUNICATIONS (2020)
In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells
Wilson Gonsalves et al.
CANCER & METABOLISM (2020)
Altered redox regulation and S-glutathionylation of BiP contribute to bortezomib resistance in multiple myeloma
Jie Zhang et al.
FREE RADICAL BIOLOGY AND MEDICINE (2020)
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability
Martina Chiu et al.
CANCERS (2020)
Actors on the Scene: Immune Cells in the Myeloma Niche
Patrizia Leone et al.
FRONTIERS IN ONCOLOGY (2020)
Plasma cells: You are what you eat
Lucas D'Souza et al.
IMMUNOLOGICAL REVIEWS (2019)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
Natural killer group 2D receptor and its ligands in cancer immune escape
Shixin Duan et al.
MOLECULAR CANCER (2019)
Mitochondrial metabolism promotes adaptation to proteotoxic stress
Peter Tsvetkov et al.
NATURE CHEMICAL BIOLOGY (2019)
Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
Lucille Stuani et al.
BMC BIOLOGY (2019)
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
Alessandro Allegra et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3
Fabrizio Puglisi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Cellular Responses to Proteasome Inhibition: Molecular Mechanisms and Beyond
Nicolas Albornoz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The emerging role of exosomes in multiple myeloma
Milad Moloudizargari et al.
BLOOD REVIEWS (2019)
Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy
Zhongping Yin et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
High Glycine Promotes Proliferation and Progression Though Increase of Glutathione Synthesis in Multiple Myeloma
Jiliang Xia et al.
BLOOD (2019)
Metabolic regulation of gene expression by histone lactylation
Di Zhang et al.
NATURE (2019)
CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma
Christopher R. Marlein et al.
CANCER RESEARCH (2019)
Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma
Hongxia Xu et al.
CLINICAL CANCER RESEARCH (2019)
Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma
Reeder M. Robinson et al.
LEUKEMIA (2019)
The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation
Katarzyna Parzych et al.
ONCOGENE (2019)
The treatment of multiple myeloma in an era of precision medicine
Nicolas Kint et al.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT (2019)
A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis
Lenka Besse et al.
HAEMATOLOGICA (2019)
Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression
Fang Ni et al.
NATURE METABOLISM (2019)
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors
Andrej Besse et al.
CELL CHEMICAL BIOLOGY (2019)
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy
Alessandra Romano et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2018)
Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming
Jason E. Conage-Pough et al.
FEBS JOURNAL (2018)
Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells
Jiancheng Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Shedding light on the cell biology of extracellular vesicles
Guillaume van Niel et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Progressive Upregulation of Oxidative Metabolism Facilitates Plasmablast Differentiation to a T-Independent Antigen
Madeline J. Price et al.
CELL REPORTS (2018)
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression
Barbara Castella et al.
FRONTIERS IN IMMUNOLOGY (2018)
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma
Christoph Driessen et al.
BLOOD (2018)
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2018)
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Andrew Spencer et al.
HAEMATOLOGICA (2018)
Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma
V Desantis et al.
TRANSLATIONAL ONCOLOGY (2018)
Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Abigail E. Overacre-Delgoffe et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy
Barbara Wegiel et al.
FRONTIERS IN ONCOLOGY (2018)
The challenges of checkpoint inhibition in the treatment of multiple myeloma
Barry Paul et al.
CELLULAR IMMUNOLOGY (2018)
Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages
Toszka Bohn et al.
NATURE IMMUNOLOGY (2018)
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy
Denise Toscani et al.
FRONTIERS IN IMMUNOLOGY (2018)
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Tomas Jelinek et al.
FRONTIERS IN IMMUNOLOGY (2018)
Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies
Wilson I. Gonsalves et al.
JCI INSIGHT (2018)
Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes
Marita Westhrin et al.
BIOMARKER RESEARCH (2018)
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers
Peter Tsvetkov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma
Nicola Giuliani et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression
Jianan Pang et al.
HAEMATOLOGICA (2017)
Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma
M. Favreau et al.
LEUKEMIA (2017)
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells
L. Poulain et al.
LEUKEMIA (2017)
The emerging roles of tumor-derived exosomes in hematological malignancies
M. Boyiadzis et al.
LEUKEMIA (2017)
CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Chang-Xin Shi et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Zdenek Skrott et al.
NATURE (2017)
Glucose feeds the TCA cycle via circulating lactate
Sheng Hui et al.
NATURE (2017)
Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche
Allison L. Boyd et al.
NATURE CELL BIOLOGY (2017)
The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy
Naoki Hosen et al.
NATURE MEDICINE (2017)
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
Ravyn M. Thompson et al.
ONCOTARGET (2017)
Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation
Madlen Effenberger et al.
ONCOTARGET (2017)
Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis
Erika M. Palmieri et al.
CELL REPORTS (2017)
Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression
Jianan Pang et al.
HAEMATOLOGICA (2017)
Comparative proteomic profiling of sera from patients with refractory multiple myeloma for predicting response to bortezomib-based therapy
Magdalena Luczak et al.
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ (2017)
CD86 regulates myeloma cell survival
Catherine M. Gavile et al.
BLOOD ADVANCES (2017)
Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study
Marianna Thordardottir et al.
BLOOD ADVANCES (2017)
HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1
Kate Vandyke et al.
CANCER RESEARCH (2017)
Lactate Metabolism in Human Lung Tumors
Brandon Faubert et al.
CELL (2017)
NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts
Christopher R. Marlein et al.
BLOOD (2017)
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Esther A. Zaal et al.
CANCER & METABOLISM (2017)
Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity
Pankaj Seth et al.
CANCER RESEARCH (2017)
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma
Vikas A. Gupta et al.
BLOOD (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate
Yi Fan et al.
CELL METABOLISM (2017)
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1
Michal Bar-Natan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Glutathione S-Transferase P-Mediated Protein S-Glutathionylation of Resident Endoplasmic Reticulum Proteins Influences Sensitivity to Drug-Induced Unfolded Protein Response
Zhi-Wei Ye et al.
ANTIOXIDANTS & REDOX SIGNALING (2017)
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Christoph Driessen et al.
HAEMATOLOGICA (2016)
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients
M. A. Frassanito et al.
LEUKEMIA (2016)
In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins
M. Martinez-Moreno et al.
LEUKEMIA (2016)
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
R. Bajpai et al.
ONCOGENE (2016)
Glutaminolysis as a target for cancer therapy
L. Jin et al.
ONCOGENE (2016)
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Christoph Driessen et al.
HAEMATOLOGICA (2016)
Extracellular matrix structure
Achilleas D. Theocharis et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
Yu-Tzu Tai et al.
BLOOD (2016)
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target
Marina Bolzoni et al.
BLOOD (2016)
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy
Ruxanda Moschoi et al.
BLOOD (2016)
miR-210 and hypoxic microvesicles: Two critical components of hypoxia involved in the regulation of killer cells function
Muhammad Zaeem Noman et al.
CANCER LETTERS (2016)
Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity
Kim De Veirman et al.
CANCER LETTERS (2016)
Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Sergei Vatolin et al.
CANCER RESEARCH (2016)
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Camille Guillerey et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake
Erik R. Abels et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2016)
Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells
Aaron M. Hosios et al.
DEVELOPMENTAL CELL (2016)
Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
H. Suen et al.
LEUKEMIA (2016)
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
G. P. Soriano et al.
LEUKEMIA (2016)
Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
K. K. Starheim et al.
BLOOD CANCER JOURNAL (2016)
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy
Dominik Dytfeld et al.
ONCOTARGET (2016)
The insulin-like growth factor system in Multiple Myeloma: diagnostic and therapeutic potential
Liesbeth Bieghs et al.
ONCOTARGET (2016)
Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells
Sophie Bustany et al.
ONCOTARGET (2016)
Microenvironment drug resistance in multiple myeloma: emerging new players
Lucia Di Marzo et al.
ONCOTARGET (2016)
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming
Irene Riz et al.
ONCOTARGET (2016)
Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy
Wen Yu et al.
ONCOTARGET (2016)
Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells
Fabrizio Antonangeli et al.
ONCOIMMUNOLOGY (2016)
GCN2 contributes to mTORC1 inhibition by leucine deprivation through an ATF4 independent mechanism
Julien Averous et al.
SCIENTIFIC REPORTS (2016)
The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches
Masahiro Kizaki et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2016)
Gene Expression Profile of Circulating Myeloma Cells Reveals CD44 and CD97 (ADGRE5) Overexpression
Tereza Sevcikova et al.
BLOOD (2016)
Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity
Nicole E. Scharping et al.
VACCINES (2016)
From Krebs to clinic: glutamine metabolism to cancer therapy
Brian J. Altman et al.
NATURE REVIEWS CANCER (2016)
Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?
Nissim Hay
NATURE REVIEWS CANCER (2016)
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells
Enrico Milan et al.
AUTOPHAGY (2015)
Treatment options for relapsed and refractory multiple myeloma
Ajay K. Nooka et al.
BLOOD (2015)
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
Nathalie Jacque et al.
BLOOD (2015)
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing
Patrizia Leone et al.
BLOOD (2015)
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Giada Bianchi et al.
BLOOD (2015)
Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
Patricia Maiso et al.
CANCER RESEARCH (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
Molecular Pathways: Is AMPK a Friend or a Foe in Cancer?
D. Grahame Hardie
CLINICAL CANCER RESEARCH (2015)
Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro
Maria Antonia Frassanito et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Metabolic Reprogramming of Immune Cells in Cancer Progression
Subhra K. Biswas
IMMUNITY (2015)
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B. Paiva et al.
LEUKEMIA (2015)
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
A. Ray et al.
LEUKEMIA (2015)
Famine versus feast: understanding the metabolism of tumors in vivo
Jared R. Mayers et al.
TRENDS IN BIOCHEMICAL SCIENCES (2015)
Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97
K. Parzych et al.
CELL DEATH & DISEASE (2015)
KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models
Irene Riz et al.
ONCOTARGET (2015)
Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation
Zhiqiang Liu et al.
ONCOTARGET (2015)
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation
Aldo M. Roccaro et al.
CELL REPORTS (2015)
Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome
Peter Tsvetkov et al.
ELIFE (2015)
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
Diego Acosta-Alvear et al.
ELIFE (2015)
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma
Barbara Castella et al.
ONCOIMMUNOLOGY (2015)
The obesity of bone
Emanuela A. Greco et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2015)
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
Anne-Marit Sponaas et al.
PLOS ONE (2015)
Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1
Shiho Fujiwara et al.
EXPERIMENTAL HEMATOLGY & ONCOLOGY (2015)
Exosomes A Novel Pathway of Local and Distant Intercellular Communication that Facilitates the Growth and Metastasis of Neoplastic Lesions
Huang-Ge Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
An Overview of Autophagy: Morphology, Mechanism, and Regulation
Katherine R. Parzych et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma
Megan E. Murray et al.
BLOOD (2014)
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death
Li Yin et al.
BLOOD (2014)
Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells
Jinheng Wang et al.
BLOOD (2014)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
Lenka Kubiczkova et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
Glutamine Oxidation Maintains the TCA Cycle and Cell Survival during Impaired Mitochondrial Pyruvate Transport
Chendong Yang et al.
MOLECULAR CELL (2014)
PKA/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells
E. A. Medina et al.
LEUKEMIA (2014)
Remodelling the extracellular matrix in development and disease
Caroline Bonnans et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
Routes and mechanisms of extracellular vesicle uptake
Laura Ann Mulcahy et al.
JOURNAL OF EXTRACELLULAR VESICLES (2014)
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Guellue Topal Goerguen et al.
BLOOD (2013)
Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
Sanne J. de Haart et al.
CLINICAL CANCER RESEARCH (2013)
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression
Aldo M. Roccaro et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Glutamine and cancer: cell biology, physiology, and clinical opportunities
Christopher T. Hensley et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Gregg L. Semenza
JOURNAL OF CLINICAL INVESTIGATION (2013)
Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow
Indu R. Ramachandran et al.
JOURNAL OF IMMUNOLOGY (2013)
PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma
Y. Zheng et al.
LEUKEMIA (2013)
The Effects of Exercise Training on Obesity-Induced Dysregulated Expression of Adipokines in White Adipose Tissue
Takuya Sakurai et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2013)
Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance
C. Bryant et al.
BLOOD CANCER JOURNAL (2013)
TNF alpha Mediated IL-6 Secretion Is Regulated by JAK/STAT Pathway but Not by MEK Phosphorylation and AKT Phosphorylation in U266 Multiple Myeloma Cells
Chansu Lee et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment
Simona Berardi et al.
JOURNAL OF ONCOLOGY (2013)
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy
E. Terpos et al.
ANNALS OF ONCOLOGY (2012)
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment
Abdel Kareem Azab et al.
BLOOD (2012)
Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy
Samuel K. McBrayer et al.
BLOOD (2012)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells
Jaehyup Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes
Arianna Calcinotto et al.
CANCER RESEARCH (2012)
Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
Anne Le et al.
CELL METABOLISM (2012)
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
Saad Z. Usmani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
The monocarboxylate transporter familyuStructure and functional characterization
Andrew P. Halestrap
IUBMB LIFE (2012)
Increased Numbers of T Helper 17 Cells and the Correlation with Clinicopathological Characteristics in Multiple Myeloma
C-J Shen et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome Inhibition
Amila Suraweera et al.
MOLECULAR CELL (2012)
Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy
Patricia Balsas et al.
LEUKEMIA RESEARCH (2012)
Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent
Sylvia Feyler et al.
PLOS ONE (2012)
Under one roof The bone marrow survival niche for multiple myeloma and normal plasma cells
Jayakumar R. Nair et al.
ONCOIMMUNOLOGY (2012)
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion
Paola Neri et al.
BLOOD (2011)
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease
Jessica A. Fowler et al.
BLOOD (2011)
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
Klaus Podar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
AMP-activated protein kinase-an energy sensor that regulates all aspects of cell function
D. Grahame Hardie
GENES & DEVELOPMENT (2011)
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Sergio A. Quezada et al.
IMMUNOLOGICAL REVIEWS (2011)
Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells
Cheryl H. Rozanski et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth
Daniela Gaglio et al.
MOLECULAR SYSTEMS BIOLOGY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma
Vito Racanelli et al.
BLOOD (2010)
Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma
Rogier M. Reijmers et al.
BLOOD (2010)
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women
Ola Landgren et al.
BLOOD (2010)
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
Jinsong Hu et al.
BLOOD (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma
Kimberly Noonan et al.
BLOOD (2010)
Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis
Anurag Purushothaman et al.
BLOOD (2010)
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
Rao H. Prabhala et al.
BLOOD (2010)
Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis
R. -M. Liu et al.
FREE RADICAL BIOLOGY AND MEDICINE (2010)
Biogenesis of secretory organelles during B cell differentiation
Semra J. Kirk et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2010)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Adhesion molecules-The lifelines of multiple myeloma cells
Ben-Zion Katz
SEMINARS IN CANCER BIOLOGY (2010)
Diverse evolutionary paths to cell adhesion
Monika Abedin et al.
TRENDS IN CELL BIOLOGY (2010)
Glutathione dysregulation and the etiology and progression of human diseases
Nazzareno Ballatori et al.
BIOLOGICAL CHEMISTRY (2009)
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Abdel Kareem Azab et al.
BLOOD (2009)
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
Yuhuan Zheng et al.
BLOOD (2009)
Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
Dharminder Chauhan et al.
CANCER CELL (2009)
RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
Evangelos Terpos et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Novel Role for Glutathione S-Transferase π REGULATOR OF PROTEIN S-GLUTATHIONYLATION FOLLOWING OXIDATIVE AND NITROSATIVE STRESS
Danyelle M. Townsend et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-beta 1
Hequan Li et al.
JOURNAL OF IMMUNOLOGY (2009)
Role of nuclear glutathione as a key regulator of cell proliferation
Federico V. Pallardo et al.
MOLECULAR ASPECTS OF MEDICINE (2009)
Glutathione: Overview of its protective roles, measurement, and biosynthesis
Henry Jay Forman et al.
MOLECULAR ASPECTS OF MEDICINE (2009)
Glutathione in liver diseases and hepatotoxicity
Liyun Yuan et al.
MOLECULAR ASPECTS OF MEDICINE (2009)
Regulation of glutathione synthesis
Shelly C. Lu
MOLECULAR ASPECTS OF MEDICINE (2009)
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells
T. Rueckrich et al.
LEUKEMIA (2009)
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism
Ping Gao et al.
NATURE (2009)
Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
K. Noborio-Hatano et al.
ONCOGENE (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
Protein S-glutathionylation: a regulatory device from bacteria to humans
Isabella Dalle-Donne et al.
TRENDS IN BIOCHEMICAL SCIENCES (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction
David R. Wise et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Murine Bone Marrow Mesenchymal Stem Cells Cause Mature Dendritic Cells to Promote T-Cell Tolerance
Q. Wang et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2008)
Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis
Ralph J. DeBerardinis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
Yasser M. El-Sherbiny et al.
CANCER RESEARCH (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
CD28-mediated regulation of multiple myeloma cell proliferation and survival
Nizar J. Bahlis et al.
BLOOD (2007)
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Karin Fischer et al.
BLOOD (2007)
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma
Yazan Alsayed et al.
BLOOD (2007)
Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential
Tali Tohami et al.
FASEB JOURNAL (2007)
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress - Relevance to Parkinson disease
Noriyuki Yamamoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Immunodeficiency and immunotherapy in multiple myeloma
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
Laurence Catley et al.
BLOOD (2006)
Protein disulfide isomerase: the structure of oxidative folding
Christian W. Gruber et al.
TRENDS IN BIOCHEMICAL SCIENCES (2006)
Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma
D. Ribatti et al.
ONCOGENE (2006)
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states
Stewart H. Lecker et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Progressively impaired proteasomal capacity during terminal plasma cell differentiation
S Cenci et al.
EMBO JOURNAL (2006)
Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression
P Serafini et al.
SEMINARS IN CANCER BIOLOGY (2006)
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
T Oshima et al.
BLOOD (2005)
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
N Giuliani et al.
BLOOD (2005)
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
LA Ehrlich et al.
BLOOD (2005)
Myeloma bone disease: pathophysiology and management
E Terpos et al.
ANNALS OF ONCOLOGY (2005)
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
KES Poole et al.
FASEB JOURNAL (2005)
Chondroitin synthase 1 is a key molecule in myeloma cell-osteoclast interactions
L Yin
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells
Y Oba et al.
EXPERIMENTAL HEMATOLOGY (2005)
Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-α via TNF receptor 2 and autocrine up-regulation of MCP-1
K Jöhrer et al.
CLINICAL CANCER RESEARCH (2004)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
AJ Novak et al.
BLOOD (2004)
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses
PC Rodriguez et al.
CANCER RESEARCH (2004)
Evaluation of MYC E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays
JW Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor
IV Broek et al.
LEUKEMIA (2004)
The changing faces of glutathione, a cellular protagonist
A Pompella et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Activin A stimulates IκB-α/NFκB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors
T Sugatani et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
AH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells
TH Landowski et al.
ONCOGENE (2003)
Expression and function of chemokine receptors in human multiple myeloma
C Moller et al.
LEUKEMIA (2003)
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
T Standal et al.
BLOOD (2002)
Soluble syndecan-1 promotes growth of myeloma tumors in vivo
Y Yang et al.
BLOOD (2002)
Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma
IMS Dahl et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
PI Croucher et al.
BLOOD (2001)
Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease
SJ Choi et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
RN Pearse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Biologic sequelae of interleukin-6 induced P13-K/Akt signaling in multiple myeloma
T Hideshima et al.
ONCOGENE (2001)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma:: therapeutic applications
T Hideshima et al.
ONCOGENE (2001)
A coordinated change in chemokine responsiveness guides plasma cell movements
DC Hargreaves et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand
JH Han et al.
BLOOD (2001)
Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1
F Sanz-Rodríguez et al.
BLOOD (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Accelerated publication -: Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc
RC Osthus et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
